CompletedNot Applicable

Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients

United States100 participantsStarted 2020-09-15

Plain-language summary

The primary objective is to determine the incidence of CMV viremia and disease in pediatric allogeneic stem cell transplantation recipients who received ganciclovir prophylaxis up until day +100 by retrospective analysis.

Who can participate

Age range26 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Retrospective chart review of all pediatric patients who underwent allogeneic stem cell transplant between June 29, 2011 and December 31, 2019 at Westchester Medical Center (WMC). * ages 0-≤26 years * received an allogeneic stem cell transplantation on the pediatric bone marrow transplant service including matched unrelated donor, matched sibling donor, haploidentical donor, umbilical cord donor * received ganciclovir prophylaxis for ≥14 days Exclusion Criteria: * None listed

What they're measuring

Ganciclovir

Timeframe: June 29, 2011 through December 31, 2019

CMV viremia and disease in pediatric allogenic SCT recipients

Timeframe: June 29, 2011 through December 31, 2019

Trial details

NCT IDNCT04478474

SponsorNew York Medical College

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-12-15

View on ClinicalTrials.gov More Cytomegalovirus Infections trials